Activity of a Novel 1,3-Beta-D-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata

被引：25
|
作者：
Ghannoum, M. [1 ,2 ]
Long, L. [1 ,2 ]
Isham, N. [1 ,2 ]
Hager, C. [1 ,2 ]
Wilson, R. [1 ,2 ]
Borroto-Esoda, K. [3 ]
Barat, S. [3 ]
Angulo, D. [3 ]
机构：
[1] Case Western Reserve Univ, Ctr Med Mycol, Cleveland, OH 44106 USA
[2] Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA
[3] Scynexis Inc, Jersey City, NJ USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 12期
关键词：
Candida glabrata; fks mutation; ibrexafungerp; MK-3118;
D O I：
10.1128/AAC.01510-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity against Candida glabrata. The susceptibility of clinical strains to ibrexafungerp was determined by microdilution and time-kill assays. The MIC range against wild-type strains was 1 to 2 mu g/ml. Ibrexafungerp was also active against the majority of echinocandin-resistant strains. Time-kill studies showed 4- to 6-log-unit reductions in growth at 24 and 48 h with concentrations of 0.25 to 4 mu g/ml.
引用
收藏
页数：3
相关论文
共 50 条
12345